Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~For T2DM Cohort only:~* Body mass index (BMI) ≥ 27 kg/m2 and ≤ 40 kg/m2.~* A confirmed diagnosis of Type 2 diabetes ≥ 6 months at screening~* Current stable treatment (at least 3 months) for diabetes~* Hemoglobin A1c (HbA1c) ≥ 6.8% and ≤ 9.0%.~* For women of childbearing potential, agreement to remain abstinent or use reliable contraception during treatment period and for at least 42 days after last dose of study drug~* For men, agreement to remain abstinent or use reliable contraception and agree to refrain from donating sperm~* For NAFLD cohort only:~* BMI ≥ 25 kg/m2 and ≤ 40 kg/m2~* At screening, confirmed liver fat by ultrasound OR calculated Liver Fat ≥ 10% using variables from the NAFLD liver fat score~* Hepatic steatosis on magnetic resonance imaging (MRI; ≥ 10% average liver proton density fat fraction \[PDFF\]) prior to randomization.~Exclusion Criteria:~* Pregnant, lactating, or intending to become pregnant within 42 days after the last dose of study drug is administered~* Suspected or confirmed diagnosis of Type 1 diabetes~* Significant cardiac disease~* Any psychiatric illness that increases the risk of participation in the study~* History of severe allergic, anaphylactic, or other hypersensitivity reactions, or severe systemic bacterial, fungal, or parasitic infections~* Poor peripheral venous access~* Received blood products within 2 months before dosing~* Donation or loss of blood within 30-56 days prior to study drug administration~* Positive for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody~* Liver enzymes greater than acceptable limits~* History of eating disorders or surgical procedures for weight loss~* Active participation in a structured weight loss or dietary program~* Treatment with investigational therapy or exposure to any biological therapy~* Illicit drug use, marijuana use, or alcohol abuse~* Current use of more than one pack of cigarettes a day or equivalent nicotine- containing products~* Any serious medical condition or abnormality in clinical laboratory tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Multiple Ascending Dose BFKB8488A (Type: EXPERIMENTAL): Participants will be randomized to receive BFKB8488A. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive BFKB8488A-matching placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete